CNS Therapies.　Delievered.

What's New

READ MORE

About Us

Braizon Therapeutics is a startup company with an innovative technology for drug delivery into the brain from the blood. We are developing this breakthrough platform to efficiently deliver various therapeutic molecules to the brain. We aim to become a leading company for drug delivery to the central nervous system, providing more effective therapeutic options for patients suffering from central nervous system diseases.

About us

Overview

Board Member

Investors

Privacy policy

Removing Barriers

A biological barrier called the blood-brain barrier protects our brains, but also restricts the development of effective therapeutic drugs for CNS diseases. Braizon’s technology can pass through this barrier by carrying drugs in minute nanocapsules decorated with glucose on their surface. This technology has potential to significantly disrupt the development of the therapeutic drugs for central nervous system diseases.

The CNS Challenge

Blood Brain Barrier

Our Technology

Adoption of Transferrin receptor for BBB crossing pathway

Glossary

Develop Smarter

The research and development divisions of Braizon Therapeutics are located in Japan (Tonomachi, Kawasaki-shi, Kanagawa) and the United States of America (Cambridge, Boston, MA). There, specialized researchers actively pursue missions in multiple fields. Through alliances with pharmaceutical companies, Braizon’s technology is employed for the development of a new therapeutic drugs. In addition, research collaborations with academia institutions explore improvements of the technology and start research and development into novel therapeutics.

Pipeline

Platform Partnership

Team Braizon

Our leadership is built from a team of professionals experienced in the specific areas of research and clinical development, management, marketing, finance and collaborative alliances.

Leadership Member

Access

Company

iCONM（kawasaki)

Lab Central(Boston)